


Anticancer agent 160

Cat. No.:	HY-156186
Molecular Formula:	C ₂₈ H ₂₉ NO ₆
Molecular Weight:	475.53
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Anticancer agent 160 (Compound 6) is a natural product derived from Parthenium hysterophorus. Anticancer agent 160 is cytotoxic to HCT-116 cells, IC ₅₀ =5.0 μM ^[1] .																
IC₅₀ & Target	Caspase 3 23.4 nM (EC50)																
In Vitro	<p>M109S (0.1-10000 nM, 24-48 h) can inhibit apoptosis induced by Bax as well as Bak^[1].</p> <p>M109S (0-10 μM, 4 h) M109S suppresses Staurosporine (HY-15141 STS)-induced apoptosis in MEFs^[1].</p> <p>M109S (0-10 μM, 24 h) inhibits Etoposide (HY-13629)-induced apoptosis in Neuro2a cells^[1].</p> <p>M109S (500 nM, 24 h) inhibits Obatoclax (HY-10969A)-induced apoptosis in ARPE19 cells^[1].</p> <p>M109S (500 nM, 48 h) suppresses the conformation change (N-terminal exposure)^[1].</p> <p>M109S (500 nM, 48 h) suppresses the mitochondrial translocation of Bax^[1].</p> <p>M109S (1.0 μM, 4 h) decreases mitochondrial oxygen consumption and reactive oxygen species, whereas M109S (0.1-1 mM) increases glycolysis^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MEF(Wt, Bax only, Bak only)</td> </tr> <tr> <td>Concentration:</td> <td>0.1 nM, 1 nM, 10 nM, 100 nM, 10000 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h (WT and Bax-only), 48 h (Bak-only)</td> </tr> <tr> <td>Result:</td> <td>Showed a dose-dependent suppression of caspase activation in all three types of MEFs.</td> </tr> </table> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Showed a dose-dependent suppression of caspase activation in all three types of MEFs.</td> </tr> <tr> <td>Concentration:</td> <td>0 nM, 1.6 nM, 8 nM, 40 nM, 200 nM, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>4 h</td> </tr> <tr> <td>Result:</td> <td>Suppressed STS-induced caspase activation in a dose-dependent manner.</td> </tr> </table>	Cell Line:	MEF(Wt, Bax only, Bak only)	Concentration:	0.1 nM, 1 nM, 10 nM, 100 nM, 10000 nM	Incubation Time:	24 h (WT and Bax-only), 48 h (Bak-only)	Result:	Showed a dose-dependent suppression of caspase activation in all three types of MEFs.	Cell Line:	Showed a dose-dependent suppression of caspase activation in all three types of MEFs.	Concentration:	0 nM, 1.6 nM, 8 nM, 40 nM, 200 nM, 10 μM	Incubation Time:	4 h	Result:	Suppressed STS-induced caspase activation in a dose-dependent manner.
Cell Line:	MEF(Wt, Bax only, Bak only)																
Concentration:	0.1 nM, 1 nM, 10 nM, 100 nM, 10000 nM																
Incubation Time:	24 h (WT and Bax-only), 48 h (Bak-only)																
Result:	Showed a dose-dependent suppression of caspase activation in all three types of MEFs.																
Cell Line:	Showed a dose-dependent suppression of caspase activation in all three types of MEFs.																
Concentration:	0 nM, 1.6 nM, 8 nM, 40 nM, 200 nM, 10 μM																
Incubation Time:	4 h																
Result:	Suppressed STS-induced caspase activation in a dose-dependent manner.																

Apoptosis Analysis^[1]

Cell Line:	Neuro2a
Concentration:	0 nM, 40 nM, 200 nM, 10 μM
Incubation Time:	24 h
Result:	Suppressed Etoposide -induced caspase activation in a dose-dependent manner.

Western Blot Analysis^[1]

Cell Line:	ARPE19
Concentration:	500 nM
Incubation Time:	24 h
Result:	Significantly inhibited Obatoclox-induced apoptosis in ARPE19 cells comparing to control.

Immunofluorescence^[1]

Cell Line:	iBax cells
Concentration:	500 nM
Incubation Time:	48 h
Result:	The frequency of the punctuated staining was significantly reduced by M109S.

In Vivo

M109S(10mg/kg p.o., three time in 48 h) protects the retina from the bright-light-induced photoreceptor death^[1].
M109S(i.p., 1 mg/kg, i.v., 5 mg/kg, or o.p., 10 mg/kg) is an orally bioactive cell death inhibitor penetrating blood-brain/retina-barrier^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Abca4 ^{-/-} Rdh8 ^{-/-} mice
Dosage:	10mg/kg
Administration:	Oral Gavage (PO)
Result:	Comparing to micewith M109S, the number of AF spots was similar to that detected in the dark-adapted mice

Animal Model:	Mice and Rat
Dosage:	Intraperitoneal injection (IP, 1 mg/kg), Intravenous injection (IV, 5 mg/kg), or Oral gavage (OP, 10 mg/kg).
Administration:	Intraperitoneal injection (IP, 1 mg/kg), Intravenous injection (IV, 5 mg/kg), or Oral gavage (OP, 10 mg/kg).
Result:	In mice, M109S reached 1.0 mg/mL (2.6 mM) plasma concentration within 30 min from administration, and it remained at 596± 134 ng/mL (1.6± 0.36 mM) 24 h after the oral gavage administration, the same as in rat. At 24 h after the oral gavage administration, the level of M109S in the plasma was 565.3± 188.3 nM in rats. The level of M109S in the rat

retina and brain reached 171.0 ± 52.0 nM and 222.7 ± 74.7 nM, respectively, 24 h after its oral administration.

REFERENCES

[1]. Singh CP, et al. Semisynthesis of Novel Dispiro-pyrrolizidino/thiopyrrolizidino-oxindolo/indanedione Natural Product Hybrids of Parthenin Followed by Their Cytotoxicity Evaluation. ACS Omega. 2023 Sep 14;8(38):35283-35294.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA